ClinicalTrials.gg
CompletedNCT03031912Updated Jan 12, 2026Results posted

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

A Phase 2 interventional study of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine and Saline in Ebola, sponsored by Canadian Immunization Research Network. Completed at 1 site in Canada. Open to participants aged 13 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Canadian Immunization Research Network · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
13 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal). The Duration of Study: 365 days for each participant not including screening.

Read the detailed description

The study will enroll approximately 250 participants, \~100 at 2 sites in Canada and \~100 at 2 sites in Africa. Overall \~200 participants will receive the study vaccine and 50 will receive a placebo . Sequential enrollment of five study cohorts will occur over time at each study site according to CD4 T-cell counts: Group 1 will include adult subjects with CD4 ≥ 500 cells/mm3, Group 2 CD4 > 350 and \< 500 cells/mm3, Group 3 CD4 ≥ 200 and ≤ 350 cells/mm3, Group 4 adolescents CD4 ≥ 200 cells/mm3, and Group 5 adults and adolescents CD4 ≥ 200 cells/mm3. Enrolment and vaccine administration will begin with the group with the highest CD4 count. When the D42 post-vaccination period is completed for all subjects in Group 1, and the Data Safety Monitoring Board (DSMB) has reviewed the safety data and determined that there are no concerns, enrolment and vaccination of the next CD4 cohort may begin. Similarly, when the D42 safety data for Group 2 has been reviewed/approved by the DSMB, enrolment and vaccination of participants in Group 3 may begin. Adolescents 13-17 years of age (inclusive) with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adults with CD4 ≥ 200. Adolescents 13-17 years of age (inclusive) and adults with CD4 ≥ 200 will be enrolled after D42 safety is reviewed in adolescents with CD4 ≥ 200.Within each group, participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the study vaccine or the placebo in a ratio of 4 to 1 (160:40). Participants will complete memory aids for 42 days following vaccination.

Specific procedures to be performed during the trial, as well as their prescribed times and associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each procedure are provided in Section 7.0 - Trial Procedures.

This trial will use an adaptive design based on pre-specified criteria, using an independent, external DSMB to monitor safety and immunogenicity. There will be 3 formal safety analyses performed by the DSMB. Data for at least 75% of participants must be available for each analysis. The first safety analysis will be conducted when the first group (CD4 ≥ 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The second safety analysis will be conducted when the second group (CD4 > 350 and \< 500 cells/mm3) will have completed 42 days of follow-up post vaccination. The third safety analysis will be conducted when the third group (Adults CD4 ≥ 200 and ≤ 350 cells/mm3) will have completed 42 days of follow-up post vaccination. The fourth safety analysis will be conducted when the fourth group (Adolescents CD4 ≥ 200) will have completed 42 days of follow-up post vaccination.

Results of the safety analysis will be reviewed by the DSMB, which will make recommendations to the Sponsor to continue, modify or end the trial according to the plan described briefly in Section 2.2 - Trial Diagram and in detail in Section 8.0 - Statistical Analysis Plan. In case of an outbreak of Ebola Zaire the DSMB may recommend to vaccinate subjects randomized to receive placebo with V920 provided at least 84 days of SAE follow-up is conducted.

02

Conditions studied

  • Ebola
03

In context

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

This study's enrollment of 251 is above the median of 94 across 81 interventional studies indexed under Hemorrhagic Fever, Ebola.

Browse Hemorrhagic Fever, Ebola studies →

Lead sponsor

Canadian Immunization Research Network is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -infected adult or adolescent male or non-pregnant, non-breastfeeding female, ages 13 to 65 (inclusive) at the time of screening;
  • On antiretroviral therapy with an undetectable viral load (\< 40 c/ml);
  • ≥ 200 cells/mm3;
  • Written (subject or parent) and assent (adolescent), after reading the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee
  • Free of health problems that could affect the safety of the participant, as determined by the Investigator by pertinent medical history and clinical examination prior to entry into the study;
  • Available, able, and willing to participate for all study visits and procedures;
  • Males and females who are willing to practice abstinence from sexual intercourse, or are willing to use effective methods of , from at least 30 days prior to vaccination until 2 months after vaccination.

    1. If the female partner is NOT of , the couple will only be required to use condoms, without other adjunctive contraception.
    2. For this study, a woman is considered of childbearing potential unless (≥ 1 year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)
    3. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label for example:

    i. Male condoms PLUS: ii. Oral contraceptives, either combined or progestogen alone iii. injectable progestogen iv. implants of etenogestrel or levonorgestrel v. oestrogenic vaginal ring vi. percutaneous contraceptive patches vii. intrauterine device or intrauterine system

  • Be willing to minimize blood and body fluid exposure of others for 6 weeks after vaccination

    1. Use of effective barrier prophylaxis, such as latex condoms, during penetrative sexual intercourse
    2. Avoiding the sharing of needles, razors, or toothbrushes
    3. Avoiding open-mouth kissing

Exclusion criteria

Exclusion Criteria:

  • History of prior infection with a filovirus or prior participation in a filovirus vaccine trial;
  • History of prior infection with VSV or receipt of a VSV-vectored vaccine;
  • Is a healthcare worker who has direct contact with patients
  • Presence of any febrile illness or any known or suspected acute illness on the day of any first immunization (subject may be rescheduled);
  • Clinical manifestations of systemic diseases considered by the investigator to impact safety or immunogenicity
  • Receipt of systemic (a dose ≥ 20 mg/day prednisone or equivalent) within one month, or any other cytotoxic or drug within six months;
  • Receipt of any drug within 12 months of vaccination;
  • Receipt of any within 42 days prior to study entry or any other (non-live virus) vaccine within 14 days prior to study entry.
  • History of sensitivity to any component of study vaccines per investigator brochure or package insert;
  • Any baseline laboratory screening tests which is outside of acceptable range as defined in the protocol: , AST, creatinine, , count, total white blood cell count, urine protein, urine occult blood, urine glucose (Appendix 2). To exclude transient abnormalities, the investigator may repeat a test up to twice, and if the repeat test is normal, subject may be enrolled;
  • Have an active or history of or hematologic malignancy except non-melanoma skin cancers;
  • Suspected or known alcohol and/or illicit drug abuse within the past 5 years;
  • Moderate or severe illness and/or fever >101°F (38.3ºC) within one week prior to vaccination;
  • Pregnant or breastfeeding female, or female who intends to become pregnant during the study period;
  • Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period;
  • Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
251 participants (actual)

Study arms

  • Active comparator
    Group 1: V920

    Participants randomly assigned to receive ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine.

    Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine

  • Placebo comparator
    Group 2: Placebo

    Participants randomly assigned to receive placebo. Saline: Normal saline (0.9%) was chosen as an inert substance to serve as placebo control.

    Other: Saline

Interventions

  • BiologicalV920Studies of V920V920 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.

  • OtherSaline

    Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Adverse Events Following V920 Vaccination

    The number of participants with general solicited local (at the injection site) and systemic adverse events following vaccination will be summarized. Local AES include: pain at injection site, redness at injection site, swelling at injection site Systemic AEs include: fever, arthritis, arthralgia, rash and blisters/vesicular lesions.

    Time frame: From vaccine administration up to day 14 following vaccination

  2. Number of Participants With Solicited Adverse Events Following V920 Vaccination

    The number of participants with solicited systemic adverse events following vaccination that include arthralgia, blister, joint swelling, pyrexia and rash

    Time frame: From vaccine administration up to 42 days postvaccination

  3. Number of Participants With Unsolicited Adverse Events Following V920 Vaccination

    The number of participants with unsolicited adverse events following vaccination. These include the following disorders: Blood and lymphatic system disorders, cardiac disorders, ear and labyrinth disorders, eye disorders, gastrointestinal disorders, general disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, psychiatric disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal disorders, skin and subcutaneous tissue disorders,vascular disorders.

    Time frame: From vaccine administration up to day 42 postvaccination

  4. Number of Participants With Serious Adverse Events Following V920 Vaccination

    The number of participants with solicited vaccine-related serious adverse events following V920 vaccination.

    Time frame: From vaccine administration up to day 365 following vaccination

  5. Geometric Mean Titers Induced by V920

    Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits. Cohorts 1-5.

    Time frame: Day 28 postvaccination

  6. Geometric Mean Titers Induced by V920

    Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits Only Cohort 5 received 2 doses of vaccine.

    Time frame: 28 days after LAST (second) dose of vaccine

07

Results

Posted Jan 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
Started4110401041940104010
Completed40940941940104010
Not completed1101000000
Withdrew: Lost to follow-up1101000000

Outcome measures

PrimaryNumber of Participants With Solicited Adverse Events Following V920 Vaccination

The number of participants with general solicited local (at the injection site) and systemic adverse events following vaccination will be summarized. Local AES include: pain at injection site, redness at injection site, swelling at injection site Systemic AEs include: fever, arthritis, arthralgia, rash and blisters/vesicular lesions.

Time frame:
From vaccine administration up to day 14 following vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Adverse Events Following V920 Vaccination
ParticipantsCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
Local - injection site erythema5121200000
Local - Injection site pain223203241343302
Local - Injection site swelling4001204111
Systemic - Abdominal pain4051414181
Systemic - Arthralgia1401627130101
Systemic - Blister0010001000
Systemic - Chills14041813060
Systemic - Diarrhea10121211020
Systemic - Fatigue21318524181201
Systemic - Feeling hot1107281103151
Systemic - Headache234212202225230
Systemic - Hyperhidrosis11010314071
Systemic - Joint swelling0001000000
Systemic - Myalgia122812030100
Systemic - Nausea10132303090
Systemic - Pyrexia5010004010
Systemic - Rash1122112120
PrimaryNumber of Participants With Solicited Adverse Events Following V920 Vaccination

The number of participants with solicited systemic adverse events following vaccination that include arthralgia, blister, joint swelling, pyrexia and rash

Time frame:
From vaccine administration up to 42 days postvaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Adverse Events Following V920 Vaccination
ParticipantsCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
Arthralgia92152600061
Blister1000001000
Joint swelling0011000000
Pyrexia8020107030
Rash0120002020
PrimaryNumber of Participants With Unsolicited Adverse Events Following V920 Vaccination

The number of participants with unsolicited adverse events following vaccination. These include the following disorders: Blood and lymphatic system disorders, cardiac disorders, ear and labyrinth disorders, eye disorders, gastrointestinal disorders, general disorders and administration site conditions, infections and infestations, injury, poisoning and procedural complications, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, psychiatric disorders, reproductive system and breast disorders, respiratory, thoracic and mediastinal disorders, skin and subcutaneous tissue disorders,vascular disorders.

Time frame:
From vaccine administration up to day 42 postvaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events Following V920 Vaccination
ParticipantsCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
Blood and lymphatic system disorders - Lymphadenopathy1000000000
Cardiac disorders - Angina pectoris0000100000
Ear and labyrinth disorders - Cerumen impaction0000001000
Eye disorders - Conjunctivitis allergic0000201000
Eye disorders - Eye irritation0000001000
Eye disorders - Eye pain0000001000
Gastrointestinal disorders - Abdominal pain1000001110
Gastrointestinal disorders - Abdominal pain upper0000100010
Gastrointestinal disorders - Dental caries1100101010
Gastrointestinal disorders - Diarrhea4100100001
Gastrointestinal disorders - Dyspepsia1000000000
Gastrointestinal disorders - Gastroduodenal ulcer1000100000
Gastrointestinal disorders - Gastrointestinal disorder1000000000
Gastrointestinal disorders - Malpositioned teeth1000000000
Gastrointestinal disorders - Oral papule0000100000
Gastrointestinal disorders - Peptic ulcer0010000000
Gastrointestinal disorders - Toothache0020002010
General disorders and administration site conditions - Chest pain0010000000
General disorders and administration site conditions - Fatigue6210100000
General disorders and administration site conditions - Ill-defined disorder0000002000
General disorders and administration site conditions - Injection site induration1000000000
General disorders and administration site conditions - Pain0021100000
General disorders and administration site conditions - Tenderness0000000000
Infections and infestations - Amoebic dysentery0000010000
Infections and infestations - Bronchitis1100222010
Infections and infestations - Conjunctivitis0010012010
Infections and infestations - Conjunctivitis bacterial0000001000
Infections and infestations - Cutaneous leishmaniasis0000010000
Infections and infestations - Cystitis1000000000
Infections and infestations - Furuncle1010010000
Infections and infestations - Gastroenteritis1011000000
Infections and infestations - Influenza1101000000
Infections and infestations - Malaria5110104120
Infections and infestations - Nasopharyngitis3100000000
Infections and infestations - Orchitis0000010000
Infections and infestations - Otitis media chronic0000000100
Infections and infestations - Parasitic gastroenteritis0000100000
Infections and infestations - Paronychia0000001000
Infections and infestations - Pilonidal disease1000000000
Infections and infestations - Pneumonia1000000000
Infections and infestations - Rhinitis0030412030
Infections and infestations - Sinobronchitis0010413010
Infections and infestations - Tinea pedis0000100000
Infections and infestations - Tonsillitis1000000000
Infections and infestations - Tooth abscess0000100000
Infections and infestations - Tooth infection0000200000
Infections and infestations - Typhoid fever0000100000
Infections and infestations - Upper respiratory tract infection1000000000
Infections and infestations - Urinary tract infection0000100000
Infections and infestations - Vulvovaginal mycotic infection0000100000
Injury, poisoning and procedural complications -Ankle fracture0000100000
Injury, poisoning and procedural complications - Limb injury0000100020
Injury, poisoning and procedural complications - Thermal burn0010000000
Metabolism and nutrition disorders - Decreased appetite2010000000
Musculoskeletal and connective tissue disorders - Back pain1000010000
Musculoskeletal and connective tissue disorders - Bursitis1000000000
Musculoskeletal and connective tissue disorders - Myalgia0100000000
Musculoskeletal and connective tissue disorders - Pain in extremity0000100000
Musculoskeletal and connective tissue disorders - Torticollis0000000010
Nervous system disorders - Burning sensation1000000000
Nervous system disorders - Carpal tunnel syndrome1000000000
Nervous system disorders - Dizziness0040301001
Nervous system disorders - Headache1030201130
Nervous system disorders - Cervicobrachial syndrome0100000000
Nervous system disorders - Intercostal neuralgia1000000000
Nervous system disorders - Paraesthesia0010100000
Nervous system disorders - Sciatica0100000000
Psychiatric disorders - Insomnia2010000000
Reproductive system and breast disorders - Breast pain1000000000
Reproductive system and breast disorders - Dysmenorrhoea0000001100
Reproductive system and breast disorders - Heavy menstrual bleeding0010000000
Reproductive system and breast disorders - Vaginal discharge1000000000
Respiratory, thoracic and mediastinal disorders - Bronchopneumopathy0000010000
Respiratory, thoracic and mediastinal disorders - Cough2000015131
Respiratory, thoracic and mediastinal disorders - Lung disorder1000001000
Respiratory, thoracic and mediastinal disorders - Oropharyngeal pain0000001000
Skin and subcutaneous tissue disorders - Acne0000100000
Skin and subcutaneous tissue disorders - Ecchymosis1000000000
Skin and subcutaneous tissue disorders - Hyperhidrosis0000100000
Skin and subcutaneous tissue disorders - Intertrigo0000100000
Skin and subcutaneous tissue disorders - Prurigo0000101000
Skin and subcutaneous tissue disorders - Pruritus3101001011
Vascular disorders - Diastolic hypertension1001000000
Vascular disorders - Hypertension0000100010
PrimaryNumber of Participants With Serious Adverse Events Following V920 Vaccination

The number of participants with solicited vaccine-related serious adverse events following V920 vaccination.

Time frame:
From vaccine administration up to day 365 following vaccination
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events Following V920 Vaccination
ParticipantsCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
Number of Participants With Serious Adverse Events Following V920 Vaccination2000100100
PrimaryGeometric Mean Titers Induced by V920

Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits. Cohorts 1-5.

Time frame:
Day 28 postvaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titers Induced by V920
TiterCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
Geometric Mean Titers Induced by V9201655.0 (1,151.4 to 2,378.9)18.1 (8.7 to 37.3)1124.6 (821.0 to 1,540.4)26.8 (13.8 to 52.0)868.8 (679.0 to 1,111.6)29.7 (17.5 to 50.2)1432.8 (1,091.0 to 1,881.8)30.4 (17.6 to 52.4)1191.8 (865.7 to 1,640.6)43.1 (22.8 to 81.8)
Statistical analysis
  • Cohort 1: V920 vs Cohort 1: Placebo vs Cohort 2: V920 vs Cohort 2: Placebo vs Cohort 3: V920 vs Cohort 3: Placebo vs Cohort 4: V920 vs Cohort 4: Placebo vs Cohort 5: V920 vs Cohort 5: Placebo · ANOVA · p = <0.001 · Fold difference: 42.90 · 95% CI 31.49 to 58.43
PrimaryGeometric Mean Titers Induced by V920

Geometric Mean Titers (GMTs) for ZEBOV-specific antibodies at Day 28 were calculated for each treatment group, along with two-sided 95% CIs, by exponentiating the corresponding log-transformed mean and two-sided 95% confidence limits Only Cohort 5 received 2 doses of vaccine.

Time frame:
28 days after LAST (second) dose of vaccine
Reported as:
Geometric mean · Titer
Geometric Mean Titers Induced by V920
TiterCohort 5: V920Cohort 5: Placebo
Geometric Mean Titers Induced by V9208,416.0 (6,461.9 to 10,961.1)40.3 (23.8 to 68.4)
Statistical analysis
  • Cohort 5: V920 vs Cohort 5: Placebo · ANOVA · p = <0.001 · Fold difference: 208.66 · 95% CI 115.57 to 376.72

Adverse events

Collected over 365 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: V9200/40 (0%)2/40 (5%)25/40 (62.5%)
Cohort 1: Placebo0/10 (0%)0/10 (0%)5/10 (50%)
Cohort 2: V9200/40 (0%)0/40 (0%)11/40 (27.5%)
Cohort 2: Placebo0/10 (0%)0/10 (0%)4/10 (40%)
Cohort 3: V9200/41 (0%)1/41 (2.4%)8/41 (19.5%)
Cohort 3: Placebo0/9 (0%)0/9 (0%)5/9 (55.6%)
Cohort 4: V9200/40 (0%)0/40 (0%)20/40 (50%)
Cohort 4: Placebo0/10 (0%)1/10 (10%)4/10 (40%)
Cohort 5: V9200/40 (0%)0/40 (0%)13/40 (32.5%)
Cohort 5: Placebo0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent serious events
Most frequent serious events
EventCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
MalariaInfections and infestations1/400/100/400/100/410/90/401/100/400/10
Hepatitis toxicHepatobiliary disorders1/400/100/400/100/410/90/400/100/400/10
ErysipelasInfections and infestations1/400/100/400/100/410/90/400/100/400/10
ThrombophlebitisVascular disorders1/400/100/400/100/410/90/400/100/400/10
Ankle fractureInjury, poisoning and procedural complications0/400/100/400/101/410/90/400/100/400/10
Lower limb fractureInjury, poisoning and procedural complications0/400/100/400/100/410/90/400/100/400/10
PseudarthrosisMusculoskeletal and connective tissue disorders0/400/100/400/100/410/90/400/100/400/10
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: Placebo
FatigueGeneral disorders6/402/100/400/100/410/90/400/100/400/10
MalariaInfections and infestations5/401/100/400/100/410/94/401/102/400/10
CoughRespiratory, thoracic and mediastinal disorders2/400/100/400/100/411/95/401/103/401/10
RhinitisInfections and infestations0/400/100/400/104/411/92/400/103/400/10
SinobronchitisInfections and infestations0/400/100/400/104/411/93/400/100/400/10
Back PainMusculoskeletal and connective tissue disorders0/400/100/400/100/411/90/400/100/400/10
BronchopneumopathyRespiratory, thoracic and mediastinal disorders0/400/100/400/100/411/90/400/100/400/10
DiarrhoeaGastrointestinal disorders4/400/100/400/100/410/90/400/100/401/10
NasopharyngitisInfections and infestations3/401/100/400/100/410/90/400/100/400/10
BronchitisInfections and infestations0/401/100/400/100/410/92/400/100/400/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: PlaceboTotal
<=18 years000000401012365
Between 18 and 65 years4010391041900287184
>=65 years10100000002
Age, Continuous
Age, Continuous(years)Cohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: PlaceboTotal
Mean52.1 ± 8.048.9 ± 8.648.1 ± 8.349.9 ± 746.6 ± 11.144.1 ± 8.815 ± 1.514.5 ± 1.433.1 ± 15.233.8 ± 1944 ± 16.7
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: PlaceboTotal
Female176247186207214130
Male244163233203196121
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: PlaceboTotal
Race — Black or African American215391041940104010225
Race — Multiple - Asian, White01000000001
Race — White2041000000025
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: V920Cohort 1: PlaceboCohort 2: V920Cohort 2: PlaceboCohort 3: V920Cohort 3: PlaceboCohort 4: V920Cohort 4: PlaceboCohort 5: V920Cohort 5: PlaceboTotal
Canada2051000000026
Burkina Faso123236256389246152
Senegal921641632116473
08

Study locations

1 site
  • CHUM
    Montreal, Quebec H2X 0A9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2023, 67 months.

Results were first posted in Jan 2026, 2 years 10 months after primary completion.

Of 13 phase 2 interventional studies under Hemorrhagic Fever, Ebola, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 39. This study's 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2016
First posted
Jan 26, 2017
StartActual
Aug 1, 2017
Primary completionActual
Mar 3, 2023
CompletionActual
Mar 3, 2023
Results first posted
Jan 12, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03031912
Lead sponsor
Canadian Immunization Research Network
Collaborators
Merck Sharp & Dohme LLC, International Development Research Centre, Canada, Dalhousie University, Université de Montréal, Coalition for Epidemic Preparedness Innovations, University of Ottawa, Centre Muraz, Institute for Health Research - Epidemiological Surveillance and Training (IRESSEF)
Responsible party
Joanne Langley (COORDINATING Investigator, Canadian Immunization Research Network) — Principal investigator
First posted
Jan 26, 2017
Start date
Aug 1, 2017
Primary completion
Mar 3, 2023
Completion
Mar 3, 2023
Results posted
Jan 12, 2026
Last update
Jan 12, 2026

Study contacts

Cecile Tremblay, MD
principal investigator · CHUM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: V920

Start the discussion